



Statement of consolidated Financial Results for the quarter ended 31st December, 2012

Rs. lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS

PARTICULARS	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR-TO-DATE FIGURES (UNREVIEWED/UNAUDITED) FOR THE NINE MONTHS PERIOD ENDED ON		YEAR ENDED (AUDITED)
	31-DEC-2012	30-SEP-2012	31-DEC-2011	31-DEC-2012	31-DEC-2011	31-MAR-2012
01. Gross Sales / Income from Operations	16515	17890	13596	49146	37679	52953
Less : Excise Duty	508	707	354	1692	1039	1347
Less : Sales Tax	229	267	311	823	819	1119
Net Sales / Income from Operations	15778	16916	12931	46631	35821	50487
02. Other Operating Income	1983	1116	947	3039	2463	2605
03. TOTAL INCOME FROM OPERATIONS	17761	18032	13878	49670	38284	53092
04. EXPENDITURE						
a) Cost of materials consumed	7153	5939	4617	19604	13289	18660
b) Purchases of stock-in-trade	55	238	293	488	1222	1553
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-527	481	252	-1436	117	75
d) Employee benefits expense	2447	3100	2049	7690	5601	7777
e) Depreciation and amortization expense	634	510	408	1587	1212	1583
f) Other Expenses	4109	3921	3552	11756	9325	13478
TOTAL EXPENSES	13871	14189	11171	39689	30766	43126
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3890	3843	2707	9981	7518	9966
06. Other Income	593	88	35	1055	308	350
07. Finance costs	758	583	581	1808	1741	2362
08. Exceptional Item	541	618	-	1159	-	-
09. Profit / (Loss) from ordinary activities before tax	3184	2730	2161	8069	6085	7954
10. Tax expense, including deferred tax	1061	771	504	2323	1489	2107
11. Minority Interest	-136	-140	-43	-308	-100	-114
12. Net Profit / Loss (-) from ordinary activities after tax	2259	2099	1700	6054	4696	5961
13. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3115	3115	3137	3115	3115
14. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						44086
15. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	7.20 7.20	6.74 6.71	5.91 5.91	19.30 19.30	16.56 16.56	20.53 20.53
16. Public Shareholding:						
a) Number of Shares	13,603,193	13,378,071	13,389,871	13,603,193	13,389,871	13,378,081
b) Percentage of Shareholding	43.36	42.95	42.99	43.36	42.99	42.95
16. Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered – No. of shares	-	-	-	-	-	-
b) Non – encumbered – No. of shares	-	17,769,881	17,758,081	-	17,758,081	17,769,881
Percentage (as a % of the total shareholding of promoter and promoter group)	-	100	100	-	100	100.00
Percentage (as a % of the total share capital of the company)	-	57.05	57.01	-	57.01	57.05

The stand-alone results are available on the company's web-site www.natcopharma.co.in. The Board of Directors have recommended an interim dividend of Rs. 4/- per equity share, payable on 6th March, 2013.

Dated at Hyderabad, this, the 13th February, 2013.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V.C. Mannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2012

Pending as on 01-10-2012	Nil
Received during the quarter	37
Resolved during the quarter	37
Pending as on 31-12-2012	Nil

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**



Statement of stand-alone Financial Results for the quarter and nine months ended 31st December, 2012

Rs. lakhs

PARTICULARS	THREE MONTHS ENDED (REVIEWED)			YEAR-TO-DATE FIGURES (REVIEWED) FOR THE NINE MONTHS PERIOD ENDED ON		YEAR ENDED (AUDITED)
	31-DEC- 2012	30-SEP- 2012	31-DEC- 2011	31-DEC- 2012	31-DEC- 2011	31-MAR-2012
PART I : STATEMENT OF STAND-ALONE RESULTS						
01. Gross Sales / Income from Operations	13788	15669	11406	41120	31950	44150
Less : Excise Duty	508	701	354	1687	1039	1347
Less : Sales Tax	229	267	311	823	819	1119
Net Sales / Income from Operations	13051	14701	10741	38610	30092	41684
02. Other Operating Income	1980	501	443	2984	1355	1895
03. TOTAL INCOME FROM OPERATIONS	15031	15202	11184	41594	31447	43579
04. EXPENDITURE						
a) Cost of materials consumed	5064	3786	2686	13289	8356	11768
b) Purchases of stock-in-trade	55	238	293	488	1222	1553
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-527	481	252	-1436	117	75
d) Employee benefits expense	1878	2643	1762	6449	4841	6713
e) Depreciation and amortization expense	550	466	406	1448	1162	1541
f) Other Expenses	3822	3385	3300	10513	8515	12322
TOTAL EXPENSES	10842	10999	8699	30751	24213	33972
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	4189	4203	2485	10843	7234	9607
06. Other Income	570	120	362	991	646	940
07. Finance costs	731	567	561	1742	1687	2296
08. Exceptional Items	541	618	-	1159	-	-
09. Profit / (Loss) from ordinary activities before tax	3487	3138	2286	8933	6193	8251
10. Tax expense, including deferred tax	1050	751	504	2291	1432	2038
11. Net Profit / Loss (-) from ordinary activities after tax	2437	2387	1782	6642	4761	6213
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3115	3115	3137	3115	3115
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						43632
14. Earnings per share - Basic and diluted EPS before and after extraordinary item (Rs.) - non-annualized	7.79	7.66	6.19	21.29	16.79	21.39
Part II : Select Information	7.79	7.61	6.19	21.17	16.79	21.39
15. Public Shareholding:						
a) Number of Shares	13,603,193	13,378,071	13,389,871	13,603,193	13,389,871	13,378,081
b) Percentage of Shareholding	43.36	42.95	42.99	43.36	42.99	42.95
16. Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered -	-	-	-	-	-	-
b) Non - encumbered - No. of shares	17,769,881	17,769,881	17,758,081	17,769,881	17,758,081	17,769,881
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100	100.00	100	100.00
Percentage (as a % of the total share capital of the company)	56.64	57.05	57.01	56.64	57.01	57.05

Dated at Hyderabad, this, the 13th day of February, 2013.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2012

Pending as on 01-10-2012	Nil
Received during the quarter	37
Resolved during the quarter	37
Pending as on 31-12-2012	Nil




Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and nine months ended on 31st December, 2012

Rs. lakhs

	THREE MONTHS ENDED			NINE MONTHS ENDED		PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED) 31-MAR-2012
	31-DEC-2012	30-SEP-2012	31-DEC-2011	31-DEC-2012	31-DEC-2011	
01. Segment Revenue (Net)						
a) Bulk Chemicals	6743	6416	4322	17130	12681	15662
b) Formulations	6982	7758	6683	21795	18641	27126
c) Job Work	255	314	228	725	691	896
d) Unallocated	1391	941	559	2990	734	1416
Total	15371	15429	11792	42640	32747	45100
Less : Inter-segment Revenue	340	227	608	1046	1300	1521
Net Sales / Income from Operations	15031	15202	11184	41594	31447	43579
02. Segment Results : Profit (+)/Loss (-) before tax and interest						
a) Bulk Chemicals	1614	1719	703	3986	2423	2943
b) Formulations	2531	3643	2872	9099	7883	9688
c) Job Work	208	275	190	599	558	727
d) Unallocated	1253	849	422	2692	628	1235
Total	5606	6486	4187	16376	11492	14593
Less : a) Interest	731	567	561	1742	1687	2296
b) Other unallocable expenditure	1958	2901	1702	6692	4258	4986
c) Unallocable income	(570)	(120)	(362)	(991)	(646)	(940)
Total Profit Before Tax	3487	3138	2286	8933	6193	8251
03. Capital Employed (Segment Assets - Segment Liabilities)						
a) Bulk Chemicals	37939	36456	23233	37939	23233	32093
b) Formulations	31251	30617	23914	31251	23914	28721
c) Job Work	48	172	150	48	150	178
e) Unallocated (Others)	-16688	-15695	-10613	-16688	-10613	-14246
Total	52550	51550	36684	52550	36684	46746

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 13th February, 2013. In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Exceptional item represents amount written off against a pending legal dispute. Employee benefit expenses for the quarter ended 30 September 2012 and nine months ended 31st December, 2012 include Rs. 504 lakhs and Rs. 362 lakhs pertaining to stock options vested during the earlier period. The stand-alone results are available on the company's web-site www.natcopharma.co.in. The Board of Directors have recommended an interim dividend of Rs. 4 per equity share, (Rs. 3 per equity share during nine months ended 31st December, 2011) payable on 6th March, 2013.

Dated at Hyderabad, this, the 13th day of February, 2013.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Mannapaneni
Chairman & Managing Director

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**